Drug Regulator Suspends PresVu Over Unauthorized Promotion
The Drugs Controller General of India (DCGI) took decisive action on Wednesday by suspending the product PresVu produced by Entod Pharmaceuticals. This suspension followed the company's failure to address crucial queries regarding the product's marketing and promotion. Such unauthorized promotional practices raise significant regulatory concerns in the pharmaceutical sector.
Moving forward, it is vital for pharmaceutical companies to maintain transparency and adherence to regulations to foster trust in the healthcare industry.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.